According to a recent study, IL-23 inhibitors used to treat psoriasis patients are associated with the lowest risk of paradoxical atopic dermatitis (AD) compared to other biologics.
New AD guidelines published with updated treatments and recommendations
The American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force has published updated atopic dermatitis (AD) guidelines based on new available treatments and evidence-based recommendations.
Abrocitinib safe and efficacious in AD patients with or without allergic comorbidities
According to a recent study, abrocitinib is efficacious and well tolerated in atopic dermatitis (AD) patients with or without allergic comorbidities.
Children with AD are more likely to develop non-atopic comorbidities
According to a recent study, children and adolescents with atopic dermatitis (AD) are more likely to develop multiple non-atopic comorbidities than those without AD.
Pruritus, pain are main drivers of AD impact and HRQoL, according to study
According to a recent study, pain and pruritus are the main contributors to atopic dermatitis (AD) burden and poor health-related quality of life (HRQoL).
Study shows patch tests for allergic contact dermatitis still effective in AD patients on dupilumab
According to a recent study, the use of dupilumab in patients with atopic dermatitis (AD) did not significantly affect the results of patch tests for allergic contact dermatitis.
Colloidal oatmeal as efficacious as barrier cream in Black children with AD
According to a recent study, colloidal oatmeal 1% is efficacious in treating mild-to-moderate atopic dermatitis (AD) in Black children.
EADV 2023 Day 3 Evening: Molecular Signature of Chronic Hand Eczema
Dr. Vimal Prajapati reports live from the 2023 EADV Congress in Berlin and discusses the common molecular signature of chronic hand eczema.
EADV 2023 Day 2 Afternoon: Treating Severe Atopic Dermatitis with Tapinarof 1% Cream
Dr. Vimal Prajapati reports live from the 2023 EADV Congress in Berlin and discusses tapinarof 1% cream for treating severe atopic dermatitis
EADV 2023 Day 1 Evening: Late Breakers in Atopic Dermatitis
Dr. Mark Kirchhof reports live from the 2023 EADV Congress in Berlin and discusses late breaker presentations around atopic dermatitis and prurigo nodularis.
HealthMinute.TV 